Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor–host interface

Combretastatins interrupt blood flow of solid tumor vascular networks and lead to necrosis by blocking nutrients. However, tumors recover from tumor blood flow interruption‐induced damage and develop viable rims. To investigate why cancer recurs and its prevention, we used a combretastatin derivative, Cderiv (=AC7700), and analyzed changes in tumor–host interface (T‐HI) vessels, which were closest to cancer cells in the tumor margin after tumor vessel disruption, and the microenvironment surrounding them. Treatment with Cderiv (10 mg/kg) interrupted tumor blood flow in all regions of LY80 (a variant of Yoshida sarcoma) tumor, but not T‐HI vessel blood flow. The same Cderiv dose given 72 h after 5 Gy irradiation stopped T‐HI vessel blood flow and prevented cancer recurrence. Treatment in the reverse order, however, did not affect T‐HI vessel blood flow. The greatest difference between the two treatments was the occurrence of gradual T‐HI edema with the former. Severe T‐HI edema compressed T‐HI blood vessels, so that circulation stopped. Thus, the distance between a tumor margin and its nearest functioning host vessel became much larger, and the tumor marginal region became a microenvironment that lacked a nutritional supply. Cancer cells in tumor margins received nutrients through two circulation routes: tumor vessels and T‐HI vessels. Our starvation methods, which involved treatment with Cderiv 72 h after 5 Gy irradiation, blocked both circulation routes and may have great potential as a clinical strategy to prevent cancer recurrence. Cancer cells in tumor margins receive nutrients via two circulation routes: tumor vessels and tumor‐host interface (T‐HI) vessels. Our starvation methods, administration of a combretastatin derivative at 72 h after 5 Gy irradiation, blocked both circulation routes and succeeded to prevent cancer recurrence.